Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma

20 Oct 2019

Abstract excerpt

Cisplatin is one of the most effective chemotherapeutic agents commonly used for several malignancies including oral squamous cell carcinoma (OSCC). Although cisplatin resistance is a major obstacle to effective treatment and is associated with poor prognosis of OSCC patients, the molecular mechanisms by which it develops are largely unknown. Cylindromatosis (CYLD), a deubiquitinating enzyme, acts as a tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to NF-κB Signaling Pathways
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31635163
DOI: 10.3390/ijms20205194

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell CarcinomaPMID 31635163Read ↗

Long noncoding RNA CEBPA-DT promotes cisplatin chemo-resistance through CEBPA/BCL2 mediated apoptosis in oral squamous cellular cancerSemantic proximity Read ↗

Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia.Semantic proximity Read ↗

The cylindromatosis (CYLD) gene and head and neck tumorigenesisSemantic proximity Read ↗

Increasing CYLD expression improved the prognosis by downregulating the mTOR/SREBP1/lipid metabolism pathway in HPV-negative OSCC patientsSemantic proximity Read ↗

Hippo pathway contributes to cisplatin resistant-induced EMT in nasopharyngeal carcinoma cellsSemantic proximity Read ↗

The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cellsSemantic proximity Read ↗

CYLD-Mediated Signaling and DiseasesSemantic proximity Read ↗

PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cellsSemantic proximity Read ↗

CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 PhosphorylationSemantic proximity Read ↗

CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus–Associated Head and Neck CancersSemantic proximity Read ↗

Functional nature of a novel mutant CYLD observed in pediatric lymphoblastic B-cell leukemia.Semantic proximity Read ↗

MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.